• Altimmune (NASDAQ:ALT) and the U.S. FDA have reached agreement on the efficacy and safety measures to be evaluated in the company's phase 3 trials of obesity asset pemvidutide following an end-of-phase 2 meeting.
• The phase 3 program will encompass four randomized, double-blind, placebo-controlled trials lasting 60 weeks and enroll a total of 5,000 participants. Three dosage strength will be tested -- 1.2 mg, 1.8 mg, and 2.4 mg -- and the company said it is aiming for approval of all strengths.
• Each trial will enroll subjects with different comorbidities. For example, one will enroll individuals who are obese or overweight without diabetes, another in those with high LDL cholesterol, a third in those with elevated liver fat, and a fourth in an elderly population.
• Pemvidutide is considered a novel peptide-based GLP-1/glucagon dual receptor agonist.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。